Advanced Age as a Risk Factor of Drug-Induced Diseases

Some patients are more likely to have drug-induced diseases due to a number of risk factors, such as older age. The aim of the study was to analyse the effect of older age on pharmacokinetics and pharmacodynamics of medicines and the risk of developing drug-induced diseases. The analysis of scientific literature demonstrated that changes in the functions of body organs and systems caused by natural aging processes may potentially affect pharmacokinetics and pharmacodynamics of medicines and increase the risk of adverse drug reactions. For instance, older people have a decreased cardiac output both at rest and during exercise, weight loss, loss of elasticity of elastic vessels, a reduced number of functioning nephrons, poorer renal filtration capacity, decreased liver volume, a reduced number of functioning hepatocytes, decreased hepatic blood flow. These changes directly affect absorption, metabolism, distribution, and excretion of medicines, which in turn can affect their safety profiles. Consideration of age-related changes in the functions of body organs and systems, regular monitoring of the efficacy and safety of the prescribed medicine, changing the dosage regimen, and revision of the treatment sheet by healthcare professionals will help optimize pharmacotherapy and reduce the risk of adverse reactions and drug-induced diseases in older patients.

1. Astakhova AV, Lepakhin VK. Drugs. Adverse drug reactions and safety control. 2nd ed. Moscow: Eksmo; 2008 (In Russ.)

2. Sychev DA, Ostroumova OD, Kochetkov AI, Pereverzev AP, Ostroumova TM, Klepikova MV, et al. Drug-induced diseases: epidemiology and urgency of the problem. Farmateka. 2020;27(5):77–84 (In Russ.) https://dx.doi.org/10.18565/pharmateca.2020.5.77-84

3. Angamo MT, Chalmers L, Curtain CM, Bereznicki LR. Adverse-drug-reaction-related hospitalisations in developed and developing countries: a review of prevalence and contributing factors. Drug Saf. 2016;39(9):847–57. https://doi.org/10.1007/s40264-016-0444-7

4. Hakkarainen KM, Gyllensten H, Jönsson AK, Andersson Sundell K, Petzold M, Hägg S. Prevalence, nature and potential preventability of adverse drug events — a population-based medical record study of 4970 adults. Br J Clin Pharmacol. 2014;78(1):170– 83. https://doi.org/10.1111/bcp.12314

5. Tisdale JE, Miller DA. Drug-induced diseases: prevention, detection, and management. 3rd ed. Bethesda, Md.: American Society of Health-System Pharmacists; 2018.

6. Tandon VR, Khajuria V, Mahajan V, Sharma A, Gillani Z, Mahajan A. Drug-induced diseases (DIDs): An experience of a tertiary care teaching hospital from India. Indian J Med Res. 2015;142(1):33–9. https://doi.org/10.4103/0971-5916.162093 Erratum in: Indian J Med Res. 2016;143(1):123.

7. Vuppalanchi R, Chalasani N. Risk factors for drug-induced liver disease. In: Kaplowitz N, DeLeve LD, eds. Drug-Induced Liver Disease. 3rd ed. Academic Press; 2013. P. 265–74. https://doi.org/10.1016/b978-0-12-387817-5.00016-9

8. Alhawassi TM, Krass I, Bajorek BV, Pont LG. A systematic review of the prevalence and risk factors for adverse drug reactions in the elderly in the acute care setting. Clin Interv Aging. 2014;9:2079–86. https://doi.org/10.2147/CIA.S71178

9. Tkacheva ON, Pereverzev AP, Runikhina NK, Kotovskaya YuV. Revisiting the safety of vaccination against the flu in elderly patients. Bezopasnost` i risk farmakoterapii = Safety and Risk of Pharmacotherapy. 2018;6(4):155–61 (In Russ.) https://doi.org/10.30895/2312-7821-2018-6-4-155-161

10. de Almeida AJPO, de Almeida Rezende MS, Dantas SH, deLima Silva S, de Oliveira JCPL, de Lourdes Assunção Araújo de Azevedo F, et al. Unveiling the role of inflammation and oxidative stress on age-related cardiovascular diseases. Oxid Med Cell Longev. 2020;2020:1954398. https://doi.org/10.1155/2020/1954398

11. Chinta SJ, Woods G, Rane A, Demaria M, Campisi J, Andersen JK. Cellular senescence and the aging brain. Exp Gerontol. 2015;68:3–7. https://doi.org/10.1016/j.exger.2014.09.018

12. Herrera MD, Mingorance C, Rodríguez-Rodríguez R, Alvarez de Sotomayor M. Endothelial dysfunction and aging: an update. Ageing Res Rev. 2010;9(2):142–52. https://doi.org/10.1016/j.arr.2009.07.002

13. Tesauro M, Mauriello A, Rovella V, Annicchiarico-Petruzzelli M, Cardillo C, Melino G, Di Daniele N. Arterial ageing: from endothelial dysfunction to vascular calcification. J Intern Med. 2017;281(5):471–82. https://doi.org/10.1111/joim.12605

14. Trindade M, Oigman W, Fritsch Neves M. Potential role of endothelin in early vascular aging. Curr Hypertens Rev. 2017;13(1):33– 40. https://doi.org/10.2174/1573402113666170414165735

15. Neves MF, Cunha AR, Cunha MR, Gismondi RA, Oigman W. The role of renin-angiotensin-aldosterone system and its new components in arterial stiffness and vascular aging. High Blood Press Cardiovasc Prev. 2018;25(2):137–45. https://doi.org/10.1007/s40292-018-0252-5

16. Nusbaum NJ. Aging and sensory senescence. South Med J. 1999;92(3):267–75. https://doi.org/10.1097/00007611-199903000-00002

17. Loh KY, Ogle J. Age related visual impairment in the elderly. Med J Malaysia. 2004;59(4):562–8, quiz 569.

18. Hughes SG. Prescribing for the elderly patient: why do we need to exercise caution? Br J Clin Pharmacol. 1998;46(6):531–3. https://doi.org/10.1046/j.1365-2125.1998.00842.x

19. Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004;57(1):6–14. https://doi.org/10.1046/j.1365-2125.2003.02007.x

20. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41(2):67–76. https://doi.org/10.1080/03602530902722679

21. Turnheim K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol. 2003;38(8):843– 53. https://doi.org/10.1016/s0531-5565(03)00133-5

22. Bowie MW, Slattum PW. Pharmacodynamics in older adults: a review. Am J Geriatr Pharmacother. 2007;5(3):263–303. https://doi.org/10.1016/j.amjopharm.2007.10.001

23. Halter JB, Ouslander JG, Tinetti ME, Studenski S, High KP, Asthana S, eds. Hazzard’s geriatric medicine and gerontology. 6 ed. New York: McGraw Hill; 2009.

24. Trifirò G, Spina E. Age-related changes in pharmacodynamics: focus on drugs acting on central nervous and cardiovascular systems. Curr Drug Metab. 2011;12(7):611–20. https://doi.org/10.2174/138920011796504473

25. Cusack BJ, Vestal RE. Clinical pharmacology: Special considerations in the elderly. In: Calkins E, Davis PJ, Ford AB, eds. Practice of geriatric medicine. Philadelphia: W.B. Saunders Co.; 1986. P. 115–36.

26. O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44(2):213–8. https://doi.org/10.1093/ageing/afu145

27. By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674–94. https://doi.org/10.1111/jgs.15767

28. Pazan F, Weiss C, Wehling M; FORTA. The EURO-FORTA (Fit fOR The Aged) List: International Consensus Validation of a Clinical Tool for Improved Drug Treatment in Older People. Drugs Aging. 2018;35(1):61–71. https://doi.org/10.1007/s40266-017-0514-2. Erratum in: Drugs Aging. 2018;35(7):677.

29. Hanlon JT, Schmader KE. The medication appropriateness index at 20: where it started, where it has been, and where it may be going. Drugs Aging. 2013;30(11):893–900. https://doi.org/10.1007/s40266-013-0118-4